nivolumab,ipilimumab,cabozantinib
bms,exelixis
['triplet,(-triplete)', 'kidney cancer']
first triplet data in first-line kidney cancer don't look good. progression-free survival only works in a patient subgroup, and overall survival has yet to hit. #esmo22 
Tweets from the Fierce Life Sciences editorial team